You are here / Home / News
 

TSO3: Second Quarter 2005 Financial Results

August 12, 2005

Québec City, August 12, 2005 – TSO3 Inc. (TSX: TOS) announced today its financial results for the second quarter of 2005. The Company recorded a net loss of $1,637,950 or $0.05 per share, for the second quarter of 2005, compared to a net loss of $1,578,541 or also $0.05 per share for the same period in 2004.

“The second quarter of 2005 was marked by new achievements closely related to the promotion and commercialization of our initial product, as shown by our deferred revenues of nearly $1 M,” stated Jocelyn Vézina, CEO at TSO3 Inc. “Our 125L Ozone Sterilizers are now used on a daily basis to sterilize the medical devices utilized on patients in most of our referral sites and in other hospitals who are not part of that program. We are working in close collaboration with our first users during the trial process for our devices, and we hope to receive the first purchase confirmations very soon.”

Summary of Activities for the Quarter

• Participation at the 2005 AORN (Association of periOperative Registered Nurses) Congress – the most important trade show for our industry in the United States – where we identified a considerable list of potential customers.

• Within the framework of our research into the prion, the infectious protein that causes Creutzfeldt-Jakob disease, the British government committed to realizing the next phase of testing and to finance the work in the amount of $710,000.

• The arrival of Dr. Paul S. Malchesky on our scientific committee. The former Vice President of Research and Development, Scientific Services and Investigational Studies at STERIS Corporation, Dr. Malchesky will contribute to the development of new products and their introduction to the market.

• The support of two medical device manufacturers – Richard Wolf and Volk Optical – for our technology. They will promote ozone sterilization as a method compatible with their products to our mutual customers.

• The offer of private placement on a firm underwritten basis presented by Canaccord Capital Corporation at the end of June. This round of financing was very successful, and we raised $10 M, with the potential for an additional $6.25 M through the exercise of the warrants over the next two years.

To view the analysis of the financial situation and the operating results, download the report for the second quarter.
© 2005-2008 TSO3. All Rights Reserved.